If you have been reading about lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-28. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
== Distinctions and honours == On 8 June 1961, Player was the guest on NBC's The Ford Show, Starring Tennessee Ernie Ford. In a comedy skit, he gives Tennessee Ernie Ford a golf lesson. Received the 1965 BBC Overseas Sports Personality of the Year Award. Received the 1966 Bob Jones Award from the United States Golf Association. Named Honorary Member of the Royal and Ancient Golf Club of St Andrews in 1994. Received Honorary Doctor of Laws Degree from University of St Andrews in 1995. Received Honorary Doctor of Science from the University of Ulster, Northern Ireland in 1997 The WGC-Bridgestone Invitational trophy is named the Gary Player Cup. Named Honorary Member of Carnoustie in 1999 Received Honorary Doctorate in Law, University of Dundee, Scotland in 1999 South African Sportsman of the Century award in 2000 Received the 2003 Laureus Lifetime Achievement Award at the Laureus World Sports Awards in Monte Carlo. Awarded the Order of Ikhamanga (in gold for exceptional achievement) in 2003 by President Mbeki of South Africa for excellence in golf and contribution to non-racial sport in South Africa. He was the world's first golfer to be featured on any country's postal stamp in South Africa. Has designed over 400 golf courses on six continents around the world. He received the 2006 Payne Stewart Award from the PGA Tour.
== Generator invention and history == 99mTc remained a scientific curiosity until the 1950s when Powell Richards realized the potential of technetium-99m as a medical radiotracer and promoted its use among the medical community. While Richards was in charge of the radioisotope production at the Hot Lab Division of the Brookhaven National Laboratory, Walter Tucker and Margaret Greene were working on how to improve the separation process purity of the short-lived eluted daughter product iodine-132 from tellurium-132, its 3.2-days parent, produced in the Brookhaven Graphite Research Reactor. They detected a trace contaminant which proved to be 99mTc, which was coming from 99Mo and was following tellurium in the chemistry of the separation process for other fission products. Based on the similarities between the chemistry of the tellurium-iodine parent-daughter pair, Tucker and Greene developed the first technetium-99m generator in 1958. It was not until 1960 that Richards became the first to suggest the idea of using technetium as a medical tracer.
== Side effects == The most common side effects include gastrointestinal disorders, such as dyspepsia, decreased appetite, nausea, vomiting, abdominal pain, diarrhea. Over the course of a 52-week double-blind study to detect the efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes, the most common side effects seen were nausea, diarrhea, and vomiting [20]. Some patients may experience serious adverse reactions: acute pancreatitis (symptoms include persistent severe abdominal pain, sometimes radiating to the back and accompanied by vomiting), hypoglycemia, renal impairment (which may sometimes require hemodialysis). The risk of hypoglycemia is increased if the drug is used in combination with sulfonylureas or insulin. Some more serious side effects include:
=== History === The lineage of the 1st Transportation Detachment, 2nd Mobile Corps dates back to the 2nd World War, when it was known as the Laiyuan guerilla detachment of the Jin-Cha-Ji Military district. It participated in the Chinese civil war, WW2 and the Korean war. After becoming part of the PLA Basic Engineering Corps it was deployed to build the Duku Highway in 1974 in which 47 personnel lost their lives. Prior to 1984, the transportation corps was part of the People's Liberation Army Basic Engineering Corps. The 7th Transportation Detachment assisted in disaster relief after the 2015 Tianjin explosions. The 6th Detachment of the transportation corps deployed 105 officers and 48 vehicles for urban search and rescue duties during the 2015 Shenzhen landslide.
Sources: en.wikipedia.org
Neither the participants nor the health care providers knew which treatment was being given until after the trial was completed. All participants were allowed to use a rescue pain medication, if the pain was not well controlled using the trial medications. To assess the benefits of oliceridine, participants used a numerical scale to score how severe the pain was after the surgery. The scores for the participants receiving oliceridine were compared to the scores for the participants who received placebo and those who received morphine. In the third trial, participants who had pain following various type of surgeries or due to a medical condition received at least one dose of oliceridine. Data from this trial were used only to assess the side effects of oliceridine. Oliceridine was approved for medical use in the United States in August 2020. The FDA granted approval of Olinvyk to Trevena Inc.
is the first derivative of concentration with respect to time, i.e. the change in concentration with time. It is derived from a mass balance. Clearance of a substance is sometimes expressed as the inverse of the time constant that describes its removal rate from the body divided by its volume of distribution (or total body water). In steady-state, it is defined as the mass generation rate of a substance (which equals the mass removal rate) divided by its concentration in the blood.
Humphreys is best known for his published PhD dissertation, Tearoom Trade: Impersonal Sex in Public Places (1970), an ethnographic study of anonymous male-male sexual encounters in public toilets (a practice known as "tea-rooming" in US gay slang and "cottaging" in British English). Humphreys asserted that the men participating in such activity came from diverse social backgrounds, had differing personal motives for seeking sexual partners in such venues, and variously self-perceived as "straight," "bisexual," or "gay." Because Humphreys was able to confirm that over 50% of his subjects identified as heterosexual men who were married to women, a primary thesis of Tearoom Trade is the incongruence between the private self and the social self for many of the men engaging in this form of homosexual activity. Specifically, they put on a "breastplate of righteousness" (social and political conservatism) in an effort to conceal their sexual behavior and prevent being exposed as deviants. Humphreys tapped into a theme of incongruence between one's words and deeds that has become a primary methodological and theoretical concern in sociology throughout the 20th and 21st centuries.
Ultimately, the potential for different methods of droplet creation and analysis in directed evolution droplet-based microfluidic devices allows for a variability that facilitates a large population of potential candidates for directed evolution. As a method for protein engineering, directed evolution has many applications in fields from development of drugs and vaccines to the synthesis of food and chemicals. A microfluidic device was developed to identify improved enzyme production hosts (i.e., cell factories) that can be employed industrially in various fields. An artificial aldolase was further enhanced by 30-fold using droplet-based microfluidics so that its activity resembled that of naturally occurring proteins. More recently, the creation of functional oxidases has been enabled by a novel microfluidic device created by Debon et al. The droplet-based microfluidic approach to the directed evolution has a great potential for the development of a myriad of novel proteins.
In January 1996, Wenger guided the club to their first piece of silverware as Nagoya defeated Sanfrecce Hiroshima to win the Emperor's Cup. Two months later they triumphed in the Super Cup, beating Yokohama Marinos 2–0. The success bolstered Nagoya's status in Japanese football, as well as Wenger's reputation; he was somewhat startled by the praise and idolisation that came his way. Midway through the 1996 league season, Wenger's former club Strasbourg enquired about the possibility of him returning to manage them. He turned down the offer, as he had been approached by Arsenal. David Dein had remained in contact with Wenger after their first meeting, and frequently sent him video tapes of matches to garner his opinions; "He was my personal pundit," the vice-chairman recalled. The Arsenal board rebuffed Dein's suggestion to appoint Wenger as early as 1995, but concerns over George Graham's successor Bruce Rioch meant they were more open-minded about hiring him since his stint in Japan. Wenger managed Nagoya for the final time on 28 August 1996 and delivered a farewell speech, thanking the fans in Japanese. Assessing his time in Japan, biographer Jasper Rees felt Wenger had left a mixed legacy at the club, as the immediate success was followed by fluctuating league finishes; it was not until 2010 that Nagoya (under Stojković) won their first title.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.